Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GBT

Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises

Starboard took aim at Pfizer in another blow Tuesday, saying the company has failed to deliver on what it called the "best pipeline" ever.

Investors Business Daily

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.

Pfizer stock closed flat Thursday after the company pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Investors Business Daily

Astronomers Accidentally Stumble Upon an ‘Invisible’ Galaxy

The literal path to stardom isn’t inevitable.

Inverse

From analysis to the latest developments in health,
read the most diverse news in one place.

Lanarkshire charity hosts range of activities to mark Mental Health Awareness Week

Getting Better Together (GBT) in Shotts aimed to combat the anxiety that many of us feel by bringing the community together and offering sessions which focus on health and well-being.

Daily Record

Shotts group enjoy big win at the seaside as part of Befrienders Week

The Getting Better Together team enjoyed a trip away to Blackpool and a big win at the bingo

Daily Record

These 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year

Biotech stocks are scorching right now. But the best of the best have strong gains. Those include 10 with at least 40% growth this year.

Investors Business Daily

5 Income Stocks to Turn to When Times Are Tough

The S&P 500 is coming off its four-week win streak amid signals of cooling price increases. However, inflation is still running hot near a 40-year high, which might induce the Fed to continue its policy rate hikes. We think income stocks AbbVie (ABBV), Amgen (AMGN), Pfizer (PFE), Bristol-Myers Squibb (BMY),…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Construction work starts on new community hub in Shotts

The redeveloped building will become a modern space with facilities for a wide range of activities and events

Daily Record

Stock Market Gains On Tax, Climate, Health Care Bill; 6 Breakouts Amid Mixed Week Of Earnings

The stock market gained on tax, climate health care bill. The latest week or earnings arrived with lackluster results.

Investors Business Daily

Why Pfizer's $5.4 Billion GBT Takeover Is 'Mutually Beneficial'

Pfizer inked a $5.4 billion deal Monday to buy Global Blood Therapeutics, confirming rumors that sent GBT stock skyrocketing last week.

Investors Business Daily

Benzinga Before The Bell: Elon Musk Confirms Tesla AI Day Part 2, Dogecoin Scam, BioNTech Q2 Earnings Shocker And Other Top Financial Stories Monday, August 8

CNBC Celsius Withdraws Motion To Rehire CFO

Benzinga

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion

Rumors that Pfizer is in "advanced talks" to acquire Global Blood Therapeutics for about $5 billion sent GBT stock flying Friday.

Investors Business Daily

Looking Into Global Blood Therapeutics's Return On Capital Employed

According to Benzinga Pro data, during Q1, Global Blood Therapeutics (NASDAQ:GBT) posted sales of $55.16 million. Earnings were up 7.03%, but Global Blood Therapeutics still reported an overall loss of $81.42 million.

Benzinga

New project in Shotts provides youngsters with bike maintenance skills

Getting Better Together (GBT) received £24,165 through walking charity Paths for All’s Smarter Choices, Smarter Places (SCSP) COP26 Legacy Fund.

Daily Record

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing

GBT said Friday its sickle cell treatment, Oxbryta, helped lower markers of the disorder in a real-world study, but GBT stock yo-yoed.

Benzinga

Global Blood Therapeutics Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Global Blood Therapeutics's (NASDAQ:GBT) reported sales totaled $55.16 million. Despite a 7.03% increase in earnings, the company posted a loss of $81.42 million.

Benzinga

Recap: Global Blood Therapeutics Q1 Earnings

Global Blood Therapeutics (NASDAQ:GBT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Benzinga

Recap: Global Blood Therapeutics Q4 Earnings

Global Blood Therapeutics (NASDAQ:GBT) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics

Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.